Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

公司产品研发进展 - 默克公司宣布了其药物ENFLONSIA (clesrovimab) 针对两岁以下婴幼儿在连续两个呼吸道合胞病毒季节的积极新数据 [1] - 该药物针对的是有严重RSV疾病高风险的婴幼儿群体 [1] 行业疾病领域动态 - 呼吸道合胞病毒是婴幼儿中导致严重下呼吸道感染的主要病因之一，存在明确的未满足临床需求 [1]